Journal
FUTURE MEDICINAL CHEMISTRY
Volume 5, Issue 12, Pages 1437-1450Publisher
FUTURE SCI LTD
DOI: 10.4155/fmc.13.113
Keywords
-
Categories
Funding
- NIH [1R01AI083145-01]
- Medicines for Malaria Venture
- Waite Philip Fishel Endowment fund
Ask authors/readers for more resources
Recent initiatives to develop more effective and affordable drugs, controlling mosquitoes and development of a preventative vaccine have been launched with the goal of completely eradicating malaria. To this end, Novartis (Surrey, UK) and GlaxoSmithKline (Middlesex, UK) screened their chemical libraries of approximately two million small molecules for antimalarial properties, which resulted in a set of over 20,000 highly druggable' initial hits. Efforts in academia are centered on specific pathway targets. One such high-throughput screening effort has been focused on hemozoin formation, a unique heme detoxification pathway found in the malaria parasite. This review discusses the current approaches and limitations of high-throughput screening discovery of hemozoin inhibitors. In the future, new methods must be developed to validate the mechanism of action of these hit compounds within the parasite.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available